Laura HammSenior Director, Corporate Compliance at Aimmune Therapeutics
Laura Hamm is the Senior Compliance Director at Aimmune Therapeutics, which in 2021 launched the first FDA-approved treatment for peanut allergies, and also joined forces with Nestle Health Science’s pharmaceutical division. Launching a novel therapy in parallel with both COVID and a new company integration brought unique compliance challenges and opportunities. Before joining Aimmune, Laura was Compliance Officer of med device manufacturer Stryker’s Neurovascular division, overseeing all elements of Neurovascular’s global compliance program. Laura is passionate about a collaborative approach to compliance, and empowering business partners to achieve objectives with high integrity. Prior to industry, Laura was an educator in the California public school system, focusing on literacy in low-income communities.